Liothyronine (LT3) for Heart Failure

PennMedicine, Philadelphia, PA
Heart Failure+1 More Conditionsliothyronine or placebo - Drug
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial is testing whether thyroid hormone therapy can help people with heart failure and low T3 levels.

Eligible Conditions
  • Heart Failure with Reduced Ejection Fraction
  • Hypothyroidism

Treatment Effectiveness

Phase-Based Effectiveness

1 of 3
Phase 1 & 2

Similar Trials

Study Objectives

2 Primary · 4 Secondary · Reporting Duration: continuous during intervention (14 days)

8 weeks
Actigraphy
Measure of Quality of Life
NT-proBNP levels
Peak Maximal Rate of Oxygen Consumption During Exercise (VO2 Max)
T3 Level
Day 14
Cardiac Rhythm Monitoring by 14 day Patch Rhythm Assessment

Trial Safety

Phase-Based Safety

1 of 3

Similar Trials

Trial Design

2 Treatment Groups

Liothyronine (LT3)
1 of 2
Placebo
1 of 2

Active Control

Non-Treatment Group

28 Total Participants · 2 Treatment Groups

Primary Treatment: Liothyronine (LT3) · Has Placebo Group · Phase 1 & 2

Placebo
Drug
PlaceboComparator Group · 1 Intervention: liothyronine or placebo · Intervention Types: Drug
Liothyronine (LT3)
Drug
ActiveComparator Group · 1 Intervention: liothyronine or placebo · Intervention Types: Drug

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: continuous during intervention (14 days)

Who is running the clinical trial?

National Heart, Lung, and Blood Institute (NHLBI)NIH
3,674 Previous Clinical Trials
47,133,923 Total Patients Enrolled
198 Trials studying Heart Failure
674,486 Patients Enrolled for Heart Failure
University of PennsylvaniaLead Sponsor
1,897 Previous Clinical Trials
41,217,895 Total Patients Enrolled
38 Trials studying Heart Failure
6,989 Patients Enrolled for Heart Failure
Anne R Cappola, MD,ScMPrincipal InvestigatorUniversity of Pennsylvania
1 Previous Clinical Trials
28 Total Patients Enrolled
1 Trials studying Heart Failure
28 Patients Enrolled for Heart Failure

Eligibility Criteria

Age 18+ · All Participants · 1 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You have an implanted device called an ICD.

Frequently Asked Questions

What aims is this research endeavor striving to fulfill?

"This 14-day clinical trial has one primary aim: achieving T3 Level. Secondary objectives include measuring NT-proBNP, Quality of Life through the KCCQ scale, and VO2 Max peak rate of oxygen consumption during exercise." - Anonymous Online Contributor

Unverified Answer

How many participants is this research endeavor accommodating?

"Affirmative. According to information published on clinicaltrials.gov, this medical study is still seeking patients to enroll in their trial. The initial posting date was February 11th 2020 and the listing has been updated most recently on August 2nd 2022; the investigators are looking for 28 individuals across a single site." - Anonymous Online Contributor

Unverified Answer

Are there any open enrollments for this medical experiment currently?

"This medical study, which was first shared on 2nd November 2020 is presently enrolling participants. Clinicaltrials.gov's records confirm that the trial has been updated as recently as 8th August 2022." - Anonymous Online Contributor

Unverified Answer
Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.